AVANOS MEDICAL, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $701.2M | $687.8M | $673.3M | $684.1M | $587.0M |
| Cost of revenue | $347.3M | $306.5M | $293.6M | $289.9M | $287.8M |
| Gross profit | $353.9M | $381.3M | $379.7M | $394.2M | $299.2M |
| Selling, general & administrative | $315.6M | $318.5M | $335.0M | $326.5M | $285.3M |
| Research and development | $23.3M | $26.2M | $27.2M | $29.2M | $30.6M |
| Operating income | -$61.6M | -$396.2M | $4.2M | $35.5M | -$39.0M |
| Interest expense | $7.8M | $12.2M | $15.0M | $10.0M | $3.3M |
| Pretax income | -$66.2M | -$403.3M | -$7.9M | $26.7M | -$42.1M |
| Income tax expense | $6.7M | -$17.0M | $2.0M | $5.2M | -$11.2M |
| Net income | -$72.9M | -$392.1M | -$61.8M | $50.5M | $6.3M |
| Balance Sheet | |||||
| Cash and equivalents | $89.8M | $107.7M | $87.7M | $127.7M | $118.5M |
| Current assets | $355.4M | $393.4M | $487.0M | $624.1M | $427.6M |
| Total assets | $1.1B | $1.2B | $1.7B | $1.8B | $1.6B |
| Current liabilities | $165.2M | $165.9M | $234.6M | $191.0M | $139.2M |
| Total liabilities | $295.5M | $325.7M | $456.1M | $495.7M | $333.0M |
| Total debt | $100.8M | $135.2M | $168.8M | $233.4M | $130.0M |
| Stockholders' equity | $778.2M | $828.5M | $1.2B | $1.3B | $1.3B |
| Cash Flow Statement | |||||
| Cash from operations | $74.7M | $100.7M | $32.4M | $90.9M | $87.3M |
| Depreciation and amortization | $38.9M | $45.5M | $46.1M | $47.7M | $38.3M |
| Stock-based compensation | $12.6M | $13.8M | $15.8M | $15.9M | $13.2M |
| Capital expenditure | $31.6M | $17.8M | $17.8M | $19.3M | $21.0M |
| Free cash flow | $43.1M | $82.9M | $14.6M | $71.6M | $66.3M |
| Share repurchases | $3.3M | $12.8M | $19.1M | $45.5M | $11.5M |
| Impairments | $77.0M | $336.5M | $0 | — | $7.9M |
Shares outstanding 46.8M · Free float 96.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.